

# Bicycle

## Bicycle Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference

March 11, 2021

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Mar. 11, 2021-- [Bicycle Therapeutics plc](#) (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (*Bicycle*®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 31<sup>st</sup> Annual Healthcare Conference on March 16, 2021 at 8:40 a.m. ET. The conference will be held in a virtual meeting format.

A live webcast of the fireside chat will be accessible in the Investors & Media section of Bicycle's website at [www.bicycletherapeutics.com](http://www.bicycletherapeutics.com). An archived replay of the webcast will be available for 90 days following the presentation date.

### About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as *Bicycles*®, for diseases that are underserved by existing therapeutics. *Bicycles* are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making *Bicycles* attractive candidates for drug development. Bicycle's lead product candidate, BT1718, a *Bicycle* Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit [bicycletherapeutics.com](http://bicycletherapeutics.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210311005352/en/): <https://www.businesswire.com/news/home/20210311005352/en/>

### Investor and Media Contact:

Argot Partners  
Maeve Conneighton  
[bicycle@argotpartners.com](mailto:bicycle@argotpartners.com)  
+1-212-600-1902

Source: Bicycle Therapeutics plc